Expertise in
5
conditions

Marco Cicardi

Milan, IT 
Expertise in
5
conditions
Milan, IT 

Overview

Marco Cicardi practices practicing medicine in Milan, Italy.

Mr. Cicardi is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, and High Molecular Weight Kininogen Deficiency.

He is actively involved in clinical research, co-authoring 151 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Milan, Italy
Other Locations
Cura, Italy
Sacco, Italy
IRCCS ICS Maugeri Milano Via Camaldoli, Maugeri, Italy
Pavia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Icatibant Outcome Survey (IOS) Registry
Icatibant Outcome Survey (IOS) Registry
Enrollment Status: Completed
Publish Date: October 28, 2024
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age
Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of rhC1INH for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2-13 Years of Age
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)
Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

151 Total Publications

Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: December 02, 2021

Frequently Asked Questions about Marco Cicardi

Is Marco Cicardi a top-rated expert for Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. Marco Cicardi is classified as an Elite expert for Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marco Cicardi participate in research or clinical trials?

Yes. Marco Cicardi has published 151 articles and abstracts on conditions like Angioedema. You can view a list of Marco Cicardi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cicardi's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile